title: Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
abstract: The Modern Vaccines/Adjuvants Formulation meeting aims to fill a critical gap in current vaccine development efforts by bringing together formulation scientists and immunologists to emphasize the importance of rational formulation design in order to optimize vaccine and adjuvant bioactivity, safety, and manufacturability. Session 6 on Vaccine and Adjuvant Formulation and Production provided three examples of this theme, with speakers emphasizing the need for extensive physicochemical characterization of adjuvant-antigen interactions, the rational formulation design of a CD8+ T cell-inducing adjuvant based on immunological principles, and the development and production of a rabies vaccine by a developing country manufacturer. Throughout the session, the practical importance of sound formulation and manufacturing design accompanied by analytical characterization was highlighted.
authors.affiliation: IDRI; Seattle, WA USA.
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Fox
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry*; D000818:Animals; D000941:Antigens / Q000737:chemistry* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D055598:Chemical Phenomena; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D004347:Drug Interactions; D006801:Humans; D011819:Rabies Vaccines / Q000276:immunology / Q000302:isolation & purification; D013557:Switzerland; D013678:Technology, Pharmaceutical / Q000379:methods; D014612:Vaccines / Q000737:chemistry* / Q000276:immunology / Q000302:isolation & purification*
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D011819:Rabies Vaccines; D014612:Vaccines
keywords: formulation; manufacturing; nanoparticles; physicochemical characterization; vaccine adjuvant